[Maternal pancytopenia during antenatal treatment of congenital toxoplasmosis].
BACKGROUND
The treatment of reference of congenital toxoplasmosis combines two folate synthesis inhibitors, pyrimethamine and an antibacterial sulfamide (sulfadiazine or sulfadoxine). Despite the efficacy of this combination, the possibility of eventually severe side effects must also be taken into account.


METHODS
A pancytopenia occurred at 37 weeks of amenorrhea during antenatal treatment for congenital toxoplasmosis in a tripara. The outcome was positive following administration of strong doses of parenteral folinic acid combined with platelet transfusion and broad-spectrum antibiotics.


CONCLUSIONS
Each of the molecules (pyrimethamine and antibacterial sulfamide) used for the treatment of congenital toxoplasmosis can lead to acute haematological problems. The occurrence of maternal pancytopenia however remains exceptional. It is principally related to pyrimethamine and is usually observed in the presence of factors enhancing folate deficiency.
Mubiayi
Ndaye
N
Clinique de gynécologie obstétrique et néonatologie, Pavilion Paul Gellé, Centre hospitalier de Roubaix. ndaye@club-internet.fr
Coutty
Nadège
N
Detourmignies
Laurence
L
Le Goueff
Françoise
F
Decocq
Jean
J
Delahousse
Guy
G
D000328:Adult; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D010198:Pancytopenia / Q000139:chemically induced*; D010298:Parity; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced*; D011263:Pregnancy Trimester, Third; D011739:Pyrimethamine / Q000009:adverse effects* / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000009:adverse effects* / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000009:adverse effects* / Q000627:therapeutic use*; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D013411:Sulfadiazine; D013413:Sulfadoxine; D011739:Pyrimethamine